J&J sees trial data supporting earlier CAR-T use in multiple myeloma
Bio Pharma Dive
JUNE 5, 2023
The results, which partially leaked in April, show Carvykti’s potential to be used after a drug called Revlimid fails, rather than reserved for only after several treatments do.
Let's personalize your content